Skip to content

Opening book details…

Can I read Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial on EtoBox?

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial by Ken Kato; Byoung Chul Cho; Masanobu Takahashi; Morihito Okada; Chen-Yuan Lin; Keisho Chin; Shigenori Kadowaki; Myung-Ju Ahn; Yasuo Hamamoto; Yuichiro Doki; Chueh-Chuan Yen; Yutaro Kubota; Sung-Bae Kim; Chih-Hung Hsu; Eva Holtved; Ioannis Xynos; Mamoru Kodani; Yuko Kitagawa is a Medicine article available to read on EtoBox.

What is Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial about?

## Background: Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival prospects. we report the final analysis from our study of the immune checkpoint pd-1 inhibitor nivolumab versus chemotherapy in patients with previously treated advanced oesophageal squamous cell carcinoma. ## Methods: We did a multicentre, randomised, open-label, phase 3 trial (attraction-3) at 90 hospitals and cancer centres in denmark, germany, italy, japan, south korea, taiwan, the uk, and the usa. we enrolled patients aged 20 years and older with unresectable advanced or recurrent oesophageal squamous cell carcinoma (regardless of pd-l1 expression), at least one measurable or non-measurable lesion per response evaluation criteria in solid tumors (recist) version 1.1, a baseline eastern cooperative oncology group performance status of 0-1, and who were refractory or intolerant to one previous fluoropyrimidine-based and platinum-based chemotherapy and had a life expectancy of at least 3 months. patients were randomly assigned (1:1) to either nivolumab (240 mg for 30 min every 2 weeks) or investigator's choice of chemotherapy (paclitaxel 100 mg/m for at least

Who reads Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Ken Kato; Byoung Chul Cho; Masanobu Takahashi; Morihito Okada; Chen-Yuan Lin; Keisho Chin; Shigenori Kadowaki; Myung-Ju Ahn; Yasuo Hamamoto; Yuichiro Doki; Chueh-Chuan Yen; Yutaro Kubota; Sung-Bae Kim; Chih-Hung Hsu; Eva Holtved; Ioannis Xynos; Mamoru Kodani; Yuko Kitagawa
Publisher
Elsevier BV
Published
2019
Language
EN
Field
Medicine (Health Sciences)

More by Ken Kato; Byoung Chul Cho; Masanobu Takahashi; Morihito Okada; Chen-Yuan Lin; Keisho Chin; Shigenori Kadowaki; Myung-Ju Ahn; Yasuo Hamamoto; Yuichiro Doki; Chueh-Chuan Yen; Yutaro Kubota; Sung-Bae Kim; Chih-Hung Hsu; Eva Holtved; Ioannis Xynos; Mamoru Kodani; Yuko Kitagawa

Browse all works by Ken Kato; Byoung Chul Cho; Masanobu Takahashi; Morihito Okada; Chen-Yuan Lin; Keisho Chin; Shigenori Kadowaki; Myung-Ju Ahn; Yasuo Hamamoto; Yuichiro Doki; Chueh-Chuan Yen; Yutaro Kubota; Sung-Bae Kim; Chih-Hung Hsu; Eva Holtved; Ioannis Xynos; Mamoru Kodani; Yuko Kitagawa